Cancer Research

Mersana Therapeutics, Inc. Appoints John H. Van Duzer, Ph.D., As Vice President Of Manufacturing And Pharmaceutical Sciences

CAMBRIDGE, Massachusetts, January 16 /PRNewswire/-- Mersana, a cancer therapeutics company, announced today that John H. van Duzer, Ph.D. has joined the company as Vice President of Manufacturing & Pharmaceutical Sciences. "John van Duzer adds a ...

Article - Anna Ohlden - Jan 16 2008 - 8:30am

Discovery: New Molecule In Innate Immune System

All multicellular animals have an innate immune system. When bacteria, parasites or fungi invade the organism, small protein molecules are released that eliminate the attackers. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszent ...

Article - News Staff - Jan 16 2008 - 12:55pm

P53- The Evolution Of The Guardian Of The Genome

The p53 regulatory network, the 'guardian of the genome' has, during the course of human evolution, created additional safeguards in human genes to further guard against DNA damage that could a variety of genetic diseases, according to an interna ...

Article - News Staff - Jan 16 2008 - 1:32pm

New Study Shows Biologic Therapy Enbrel(R) (etanercept) Effective In Treating Psoriasis In Children And Adolescents

MAIDENHEAD, England, January 17 /PRNewswire/-- Wyeth (WYE) today announced data from a Phase 3 study which showed that Enbrel significantly reduces the symptoms and signs of plaque psoriasis in children and adolescents with the disease.(1) This study was ...

Article - Anna Ohlden - Jan 16 2008 - 7:30pm

In Defense Of Sugar

Sugars were once credited with magical healing powers but are now seen like salt as an evil necessary in small doses but the cause of numerous diseases such as diabetes if taken in excess. Yet latest research suggests this view ignores the vital role playe ...

Article - News Staff - Jan 17 2008 - 11:41am

ThromboGenics And BioInvent Receive Approval To Begin Clinical Trials Of TB-403 For The Treatment Of Cancer

LEUVEN, Belgium and LUND, Sweden, January 18 /PRNewswire/-- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (Nordic Exchange: BINV) announce today that they have received approval from the regulatory authori ...

Article - Anna Ohlden - Jan 18 2008 - 1:30am

ProMetic And MacoPharma Announce Successful Completion Of P-Capt(R) Prion Reduction Filter Clinical Studies

CAMBRIDGE, England and LILLE, France, January 18 /PRNewswire/--- Irish and UK Blood Services Continue Pre-Adoption Clinical Evaluation of Filter- Recent Case of vCJD Now Means That All the Population is Susceptible to the Disease- Increased Concerns Over ...

Article - Anna Ohlden - Jan 18 2008 - 4:30am

Do Antioxidant Supplements Reduce Cancer?

Do antioxidant supplements reduce the risk of cancer and deaths related to cancer? While some trials have suggested that antioxidants have beneficial effects, results from other trials have been negative. It has been unclear which antioxidant compounts are ...

Article - News Staff - Jan 19 2008 - 11:41am

Your Next Biopsy Could Be Virtual

A non-invasive diagnostic tool to detect surface cancers quickly and painlessly using technology currently employed by gyms to calculate body composition has been developed by a QUT PhD medical physics researcher. Jye Smith from QUT’s School of Physical an ...

Article - News Staff - Jan 19 2008 - 11:46am

ImmunoVaccine Technologies Receives $3 Million From ACOA

HALIFAX, Canada, January 21 /PRNewswire/-- ImmunoVaccine Technologies Inc. (IVT), a clinical stage vaccine development company, will receive CAD $3 Million from the Atlantic Canada Opportunities Agency (ACOA), under the Atlantic Innovation Fund (AIF). Thi ...

Article - Anna Ohlden - Jan 21 2008 - 11:31am